15 October 2018 in Headache: The Journal of Head and Face Pain
17 June 2016 in Headache: The Journal of Head and Face Pain
Objective: To provide a summary of knowledge about the use of melatonin in the treatment of primary headache disorders. Background: Melatonin is secreted by the pineal gland; its production is regulated by the hypothalamus and increases during periods of darkness. Methods: We undertook a narrative review of the literature on the role of melatonin in the treatment of primary headache disorders. Results: There are randomized placebo‐controlled trials examining melatonin for preventive treatment of migraine and cluster headache. For cluster headache, melatonin 10 mg was superior to placebo. For migraine, a randomized placebo‐controlled trial of melatonin 3 mg (immediate release) was positive, though an underpowered trial of melatonin 2 mg (sustained release) was negative. Uncontrolled studies, case series, and case reports cover melatonin's role in treating tension‐type headache, hypnic headache, hemicrania continua, SUNCT/SUNA and primary stabbing headache. Conclusions: Melatonin may be effective in treating several primary headache disorders, particularly cluster headache and migraine. Future research should focus on elucidating the underlying mechanisms of benefit of melatonin in different headache disorders, as well as clarifying optimal dosing and formulation.
23 November 2017 in The Journal of Headache and Pain
The 2013 International Classification of Headache Disorders-3 (ICHD-3) was published in a beta version to allow the clinicians to confirm the validity of the criteria or to suggest improvements based on field studies. The aim of this work was to review the Primary Headache Disorders Section of ICHD-3 beta data on children and adolescents (age 0-18 years), and to suggest changes, additions, and amendments. Several experts in childhood headache across the world applied different aspects of ICHD-3 beta in their normal clinical practice. Based on their personal experience and the literature available on pediatric headache, they made observations and proposed suggestions for the primary headache disorders section of ICHD-3 beta data on children and adolescents. Some headache disorders in children have specific features which are different from those seen in adults and which should be acknowledged and considered. Some features in children were found to be age-dependent: clinical characteristics, risks factors and etiologies have a strong bio psycho-social basis in children and adolescents making primary headache disorders in children distinct from those in adults. Several recommendations are presented in order to make ICHD-3 more appropriate for use with children.
1 February 2016 in Seminars in Pediatric Neurology
1 November 2019 in Neurologic Clinics
3 August 2015 in Headache: The Journal of Head and Face Pain